Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Acumen Pharmaceuticals Inc (ABOS)

Acumen Pharmaceuticals Inc (ABOS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 124,780
  • Shares Outstanding, K 60,573
  • Annual Sales, $ 0 K
  • Annual Income, $ -102,330 K
  • EBIT $ -138 M
  • EBITDA $ -143 M
  • 60-Month Beta 0.25
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.39

Options Overview Details

View History
  • Implied Volatility 445.83% (+222.55%)
  • Historical Volatility 93.38%
  • IV Percentile 81%
  • IV Rank 49.66%
  • IV High 790.23% on 08/13/25
  • IV Low 106.07% on 12/17/24
  • Expected Move (DTE 3) 0.38 (18.48%)
  • Put/Call Vol Ratio 80.00
  • Today's Volume 81
  • Volume Avg (30-Day) 52
  • Put/Call OI Ratio 0.05
  • Today's Open Interest 2,255
  • Open Int (30-Day) 2,289
  • Expected Range 1.69 to 2.45

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.50
  • Number of Estimates 2
  • High Estimate -0.44
  • Low Estimate -0.56
  • Prior Year -0.62
  • Growth Rate Est. (year over year) +19.35%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.50 +38.47%
on 11/17/25
2.19 -5.16%
on 12/12/25
+0.35 (+20.06%)
since 11/14/25
3-Month
1.22 +70.25%
on 09/23/25
2.46 -15.57%
on 10/28/25
+0.85 (+68.86%)
since 09/16/25
52-Week
0.86 +142.90%
on 04/21/25
2.46 -15.57%
on 10/28/25
+0.11 (+5.43%)
since 12/16/24

Most Recent Stories

More News
Acumen Pharmaceuticals Highlights Enhanced Brain Delivery™ Technology for Oligomer-Selective Antibodies and Recruitment Strategies for Phase 2 ALTITUDE-AD Clinical Trial at 18th Annual Clinical Trials on Alzheimer’s Disease (CTAD) Conference

NEWTON, Mass., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc.  (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets soluble amyloid...

ABOS : 2.07 (+0.49%)
Acumen Pharmaceuticals to Present on Recruitment Strategies for Phase 2 ALTITUDE-AD Trial and Enhanced Brain Delivery Technology at 18th Annual Clinical Trials on Alzheimer’s Disease (CTAD) Conference

NEWTON, Mass., Nov. 18, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets soluble amyloid beta...

ABOS : 2.07 (+0.49%)
Acumen Pharmaceuticals Announces First Participant Dosed in Phase 2 Open-Label Extension Study of Sabirnetug in People with Early Alzheimer’s Disease

NEWTON, Mass., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets soluble amyloid beta...

ABOS : 2.07 (+0.49%)
Acumen Pharmaceuticals Reports Third Quarter 2025 Financial Results and Business Highlights

Expect decision regarding the advancement of an Aβ oligomer-targeted Enhanced Brain Delivery TM product candidate in early 2026 Expect to report topline results for ALTITUDE-AD, a Phase 2 study to...

ABOS : 2.07 (+0.49%)
Acumen Pharmaceuticals Appoints George Golumbeski, Ph.D., as Chairman of its Board of Directors

NEWTON, Mass., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics...

ABOS : 2.07 (+0.49%)
Acumen Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 12, 2025

NEWTON, Mass., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing a novel therapeutic...

ABOS : 2.07 (+0.49%)
Acumen Pharmaceuticals to Participate in the Stifel Healthcare Conference

NEWTON, Mass., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble amyloid...

ABOS : 2.07 (+0.49%)
2 ‘Strong Buy’ Stocks That Wall Street Believes Can Soar 360% to 780%

These two growth stocks are attractive for investors seeking big upside in exchange for higher risk.

ELDN : 1.6250 (-0.91%)
$SPX : 6,772.22 (-0.65%)
ABOS : 2.07 (+0.49%)
Acumen Pharmaceuticals to Participate in Upcoming Investor Conferences

NEWTON, Mass., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble amyloid...

ABOS : 2.07 (+0.49%)
Acumen Pharmaceuticals Reports Second Quarter 2025 Financial Results and Business Highlights

Expect to report topline results for ALTITUDE-AD, a Phase 2 study to investigate sabirnetug (ACU193) for the treatment of early Alzheimer’s disease, in late 2026 Expect decision to advance an oligomer-targeted...

ABOS : 2.07 (+0.49%)

Business Summary

Acumen Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It involved in developing a novel disease for Alzheimer. The company's product pipeline consist ACU193. Acumen Pharmaceuticals Inc. is based in CHARLOTTESVILLE, Va.

See More

Key Turning Points

3rd Resistance Point 2.33
2nd Resistance Point 2.24
1st Resistance Point 2.15
Last Price 2.07
1st Support Level 1.97
2nd Support Level 1.88
3rd Support Level 1.79

See More

52-Week High 2.46
Last Price 2.07
Fibonacci 61.8% 1.85
Fibonacci 50% 1.66
Fibonacci 38.2% 1.47
52-Week Low 0.86

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar